BNR Burning Rock Biotech ADS (N Shares)

Burning Rock Announces Preliminary Fourth Quarter and Full Year 2020 Results and Schedules Earnings Release on March 11, 2021

Burning Rock Announces Preliminary Fourth Quarter and Full Year 2020 Results and Schedules Earnings Release on March 11, 2021

GUANGZHOU, China, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited fourth quarter and full year 2020 financial results before the U.S. market opens on March 11, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET on (9:00 p.m. Hong Kong time) the same day to discuss its financial results for the fourth quarter and full year 2020.

Details of the conference call are as follows:

International:
U.S.:
U.K.:
Hong Kong:
China Mobile:4006208038
China Landline:8008190121
Conference ID:5266945

A replay of the fourth quarter and full year 2020 financial results conference call will be available for one week (dial-in number: ; same conference ID as shown above).

Please visit the company’s investor relations website at /news-events/news-releases on March 11, 2021 to view the earnings release prior to the conference call.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact:



EN
09/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Burning Rock Biotech ADS (N Shares)

 PRESS RELEASE

Burning Rock Reports First Quarter 2025 Financial Results

Burning Rock Reports First Quarter 2025 Financial Results GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oeso...

 PRESS RELEASE

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Finan...

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2024. 2024 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well ...

 PRESS RELEASE

Burning Rock Announces Results of 2024 Annual General Meeting

Burning Rock Announces Results of 2024 Annual General Meeting GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP a...

 PRESS RELEASE

Burning Rock Announces 2024 Annual General Meeting to be Held on Decem...

Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024 GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 31, 2024 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of ...

 PRESS RELEASE

NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Com...

NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China GUANGZHOU, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision oncology, and Dizal, a global biopharmaceutical company focused on malignant tumors and immunological diseases, jointly announced that the companion diagnostic (CDx) for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, developed through their collaboration, has been approved by the National...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch